| Differential expression of survivin-2B and survivin-ΔEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC) X Ling, J Yang, DF Tan, N Ramnath, T Younis, BN Bundy, HK Slocum, ... Lung Cancer 49 (3), 353-361, 2005 | 75 | 2005 |
| Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer NWD Lamond, C Skedgel, D Rayson, L Lethbridge, T Younis Breast cancer research and treatment 133, 1115-1123, 2012 | 63 | 2012 |
| Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening … D Rayson, JI Payne, M Abdolell, PJ Barnes, RF MacIntosh, T Foley, ... Clinical breast cancer 11 (1), 27-32, 2011 | 62 | 2011 |
| Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis T Younis, D Rayson, K Thompson Supportive Care in Cancer 20, 2523-2530, 2012 | 59 | 2012 |
| The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada A Drucker, C Skedgel, K Virik, D Rayson, M Sellon, T Younis Current oncology 15 (3), 136-142, 2008 | 58 | 2008 |
| Wait times for breast cancer care N Saint-Jacques, T Younis, R Dewar, D Rayson British journal of cancer 96 (1), 162-168, 2007 | 47 | 2007 |
| Trastuzumab for HER2-positive metastatic breast cancer: clinical and economic considerations A Jeyakumar, T Younis Clinical Medicine Insights: Oncology 6, CMO. S6460, 2012 | 46 | 2012 |
| The costutility of sequential adjuvant trastuzumab in women with Her2/Neupositive breast cancer: An analysis based on updated results from the HERA Trial C Skedgel, D Rayson, T Younis Value in Health 12 (5), 641-648, 2009 | 44 | 2009 |
| Adjuvant chemotherapy uptake in non-small cell lung cancer T Younis, T Al-Fayea, K Virik, W Morzycki, N Saint-Jacques Journal of Thoracic Oncology 3 (11), 1272-1278, 2008 | 44 | 2008 |
| Waiting times in early-stage non-small cell lung cancer (NSCLC) N Saint-Jacques, D Rayson, T Al-Fayea, K Virik, W Morzycki, T Younis Journal of Thoracic Oncology 3 (8), 865-870, 2008 | 39 | 2008 |
| The cost–utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer T Younis, D Rayson, C Skedgel Current Oncology 18 (6), 288-296, 2011 | 37 | 2011 |
| Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole C Skedgel, D Rayson, R Dewar, T Younis Breast cancer research and treatment 101, 325-333, 2007 | 36 | 2007 |
| Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100 T Younis, D Rayson, M Sellon, C Skedgel Breast cancer research and treatment 111, 261-267, 2008 | 35 | 2008 |
| Drug-induced subacute cutaneous lupus erythematosus associated with nab-paclitaxel therapy NWD Lamond, T Younis, K Purdy, MS Dorreen Current OnCOlOgy 20 (5), 484-487, 2013 | 34 | 2013 |
| Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and … M Benekli, SL Smiley, T Younis, MS Czuczman, F Hernandez-Ilizaliturri, ... Bone marrow transplantation 41 (7), 613-619, 2008 | 32 | 2008 |
| Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects HJ Au, K Golmohammadi, T Younis, S Verma, S Chia, K Fassbender, ... Breast cancer research and treatment 114, 579-587, 2009 | 30 | 2009 |
| Comparison of elapsed times from breast cancer detection to first adjuvant therapy in Nova Scotia in 1999/2000 and 2003/04 D Rayson, N Saint-Jacques, T Younis, J Meadows, R Dewar Cmaj 176 (3), 327-332, 2007 | 30 | 2007 |
| Length of survival in hospice for cancer patients referred from a comprehensive cancer center T Younis, R Milch, N Abul-Khoudoud, D Lawrence, A Mirand, E Levine American Journal of Hospice and Palliative Medicine® 26 (4), 281-287, 2009 | 28 | 2009 |
| Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray K Dakin Haché, S Gray, PJ Barnes, R Dewar, T Younis, D Rayson Breast cancer research and treatment 105, 169-175, 2007 | 28 | 2007 |
| Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. TH Younis British journal of haematology 121 (1), 2003 | 28 | 2003 |
